IP Verse

Expansion Of Lymphocytes With A Cytokine Composition For Active Cellular Immunotherapy - EP3154567

The patent EP3154567 was granted to Polybiocept on Nov 25, 2020. The application was originally filed on Jun 11, 2015 under application number EP15737995A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3154567

POLYBIOCEPT
Application Number
EP15737995A
Filing Date
Jun 11, 2015
Status
Granted And Under Opposition
Oct 23, 2020
Grant Date
Nov 25, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MARGARET DIXONAug 25, 2021MEWBURN ELLISADMISSIBLE
STRAWMANAug 25, 2021SAGITTARIUSADMISSIBLE

Patent Citations (11) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
EXAMINATIONWO2010056144
EXAMINATIONWO2015189301
INTERNATIONAL-SEARCH-REPORTWO2007071390
INTERNATIONAL-SEARCH-REPORTWO2007071409
INTERNATIONAL-SEARCH-REPORTWO2008066609
OPPOSITIONCN103756964
OPPOSITIONGB2484869
OPPOSITIONUS2012121544
OPPOSITIONWO2010056144
OPPOSITIONWO2012129201
OPPOSITIONWO2015189301

Non-Patent Literature (NPL) Citations (14) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- MARKEL et al., "Preclinical Evaluation of Adoptive Cell Therapy for Patients with Metastatic Renal Cell Carcinoma", Anticancer Research, (20090000), vol. 29, pages 145 - 154, XP055741669-
OPPOSITION- PARK et al., "Interleukin-21 Increases Direct Cytotoxicity and IFN-γ Production of Ex Vivo Expanded NK Cells towards Breast Cancer Cells", Anticancer Research, (20120000), vol. 32, no. 3, pages 839 - 346, XP055844141-
OPPOSITION- LI et al., "Efficient Treg depletion induces T-cell infiltration and rejection of large tumors", Eur. J. Immunol., (20100000), vol. 40, pages 3325 - 3335, XP055844150
OPPOSITION- MERAVIGLIA et al., "Vγ9Vδ2 T cells as a promising innovative tool for immunotherapy of hematologic malignancies", Oncol. Rev., (20100000), vol. 4, pages 211 - 218, XP055844147
OPPOSITION- Huarte, E. ; Fisher, J. ; Turk, M.J. ; Mellinger, D. ; Foster, C. ; Wolf, B. ; Meehan, K.R. ; Fadul, C.E. ; Ernstoff, M.S., "Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma", CANCER LETTERS, US, (20091118), vol. 285, no. 1, doi:10.1016/j.canlet.2009.05.003, ISSN 0304-3835, pages 80 - 88, XP026643980
OPPOSITION- LIM et al., "Effect of exposure to interleukin-21 at various time points on human natural killer cell culture", Cytotherapy, (2014), vol. 16, pages 1419 - 1430, XP055844142
OPPOSITION- NICOL et al., "Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours", BJC, (20110000), vol. 105, pages 778 - 786, XP002756021
OPPOSITION- BEDOGNETTI et al., "CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2", BJC, (20130000), vol. 109, pages 2412 - 2423, XP055844156
OPPOSITION- GATTINONI ET AL. et al., "A human memory T cell subset with stem cell-like properties", Nature Medicine, (20110000), vol. 17, no. 10, pages 1290 - 1298, XP009168103
OPPOSITION- HERNANDEZ-CHACON, "Co-stimulation Through the CD137/4-1BB Pathway Protects Human Melanoma Tumor-infiltrating Lymphocytes From Activation-induced Cell Death and Enhances Antitumor Effector Function", J Immunother, (20110400), vol. 34, no. 3, pages 236 - 250, XP055568325
OPPOSITION- Wu R; Forget M -A; Chacon J; Bernatchez C; Haymaker C; Chen J Q; Hwu P; Radvanyi L G, "Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: Current status and future outlook", CANCER JOURNAL, US, (20120301), vol. 18, no. 2, doi:10.1097/PPO.0b013e31824d4465, ISSN 1528-9117, pages 160 - 175, XP009170931
OPPOSITION- FEUCHT et al., "Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT", Blood, (20150319), vol. 125, no. 12, pages 1986 - 1994, XP055844154
OPPOSITION- MENG et al., "Generation of tumor-infiltrating lymphocytes from pancreatic cancer lesions for cellular therapy", J. ImmunoTherapy of Cancer, (2014), vol. 2, no. Suppl 3, page P26, XP021202529
OPPOSITION- FRUMENTO et al., "CD117 (c-Kit) Is Expressed During CD8+ T Cell Priming and Stratifies Sensitivity to Apoptosis According to Strength of TCR Engagement", Frontiers in Immunology, (20190300), vol. 10, pages 1 - 13, XP055844162

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents